首页|期刊导航|肿瘤防治研究|硼中子俘获治疗现状及发展方向

硼中子俘获治疗现状及发展方向OA

Current Status and Future Development of Boron Neutron Capture Therapy

中文摘要英文摘要

硼中子俘获治疗(BNCT)作为一种精准肿瘤治疗技术,国际上以日本为代表已进入成熟临床阶段.中国起步虽晚,但凭借自主研发,在加速器中子源设备、硼药国产化及临床疗效验证等方面实现快速发展,部分指标达到国际先进水平.未来需聚焦第三代硼药研发、治疗规范、治疗成本的降低与可及性的提升,以构建具有竞争力的BNCT临床应用与技术创新体系.

Boron neutron capture therapy(BNCT)is a precision radiotherapy technology for tumors.On the international stage,Japan stands out as a representative country where BNCT has progressed into a mature clinical phase.Although China started relatively late,it has achieved rapid advancements through independent research and development in accelerator and neutron source equipment,domestically produced boron drugs,and clinically validated therapeutic efficacy.In several key indicators,China has now reached internationally advanced levels.Looking ahead,efforts should be prioritized toward the development of third-generation boron-based drugs,the standardization of treatment protocols,and cost reduction to enhance treatment accessibility,ultimately aiming to build a competitive BNCT clinical application and technological innovation system.

马佳;柏预立;韩光

430079 武汉,华中科技大学同济医学院附属湖北肿瘤医院放射治疗中心430079 武汉,华中科技大学同济医学院附属湖北肿瘤医院放射治疗中心430079 武汉,华中科技大学同济医学院附属湖北肿瘤医院放射治疗中心

医药卫生

硼中子俘获治疗临床现状研究进展

Boron neutron capture therapyClinical treatment statusResearch development

《肿瘤防治研究》 2026 (4)

243-250,8

Talent Project of Hubei Cancer Hospital(No.2025HBCHQHRC011) 湖北省肿瘤医院启航人才项目(2025HB-CHQHRC011)

10.3971/j.issn.1000-8578.2026.25.0967

评论